Urinary oxalate excretion and its role in vulvar pain syndrome


      Objective: This study was undertaken to determine the urinary oxalate excretion patterns in patients with vulvodynia compared with controls and to evaluate antioxalate therapy in women with vulvar pain syndrome (vulvodynia). Study design: A total of 130 consecutive patients with vulvar pain syndrome and 23 volunteers without symptoms collected urine specimens for 24 hours; each voiding was saved in individual labeled containers and refrigerated. The specimens were analyzed individually for oxalate and calculated according to 24-hour concentration, volume, and peak oxalate by hour. A total of 59 patients were treated with low-oxalate diets and calcium citrate for 3 months and evaluated for objective relief of vulvar pain. Results: The 24-hour excretion of oxalate was almost identical in controls and vulvodynia patients. The total 24-hour excretion was directly proportional to the volume of urine excreted (p < 0.001). No significant differences were found in peak oxalate excretion (95% confidence intervals). The number of voidings was higher in the vulvodynia cohort (p < 0.02). The 59 women with elevated oxalate concentrations (>1 mg/40 dl) were treated with an antioxalate regimen. Fourteen (24%) demonstrated an objective response, but only 6 (10%) could have pain-free sexual intercourse. Conclusions: Urinary oxalates may be nonspecific irritants that aggravate vulvodynia; however, the role of oxalates as instigators is doubtful.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Friedrich Jr, EG
        Vulvar vestibulitis syndrome.
        J Reprod Med. 1987; 32: 110-114
        • Solomons CC
        • Melmed MH
        • Heitler SM
        Calcium citrate for vulvar vestibulitis: a case report.
        J Reprod Med. 1991; 36: 879-882
        • Archer HE
        • Dormer AE
        • Scowen EG
        • Watts RWE
        Studies on the urinary excretion of oxalate by normal subjects.
        Clin Sci. 1957; 16: 405-409
        • Woodruff JD
        • Parmley TH
        Infection of the minor vestibular glands.
        Obstet Gynecol. 1983; 62: 609-612
        • Woodruff JD
        • Friedrich Jr, EG
        The vestibule.
        Clin Obstet Gynecol. 1985; 28: 134-142
        • Baggish MS
        • Miklos JR
        Vulvar pain syndrome: a review.
        Obstet Gynecol Surv. 1995; 50: 618-627
        • Reid R
        • Omoto KH
        • Precop SL
        • Berman NR
        • Rutledge LH
        • Dean SM
        • et al.
        Flashlamp-excited dye laser therapy of idiopathic vulvodynia is safe and efficacious.
        Am J Obstet Gynecol. 1995; 172: 1684-1701
        • Horowitz BJ
        Interferon therapy for condylomatous vulvitis.
        Obstet Gynecol. 1989; 73: 446-448
        • Davis GD
        The management of vulvar vestibulitis syndrome with the CO laser.
        J Gynecol Surg. 1989; 5: 87-91
        • Reid R
        • Greenburg MD
        • Daoud YD
        • et al.
        Colposcopic findings in women with vulvar pain syndrome.
        J Reprod Med. 1988; 33: 523-532
        • Glaser H
        • Rodke G
        • Swencionis C
        • et al.
        The treatment of vulvar vestibulitis syndrome by electromyographic biofeedback of pelvic floor muscles.
        J Reprod Med. 1995; 40: 283
        • Melmed HM
        A low calcium oxalate diet and calcium citrate administration are effective treatments for vulvar pain syndrome.
        J Gynecol Surg. 1996; 12: 217-218